The burden of severe hypoglycemia in type 1 diabetes

Liu, Jieruo; Wang, Rosa; Ganz, Michael L.; Paprocki, Yurek; Schneider, Doron; Weatherall, James C.

doi:10.1080/03007995.2017.1391079

Cited by 37 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, Liu et al . [ 19 ] examined the related factors to quality of life including depression, social rank, and gender in patients with type 2 diabetes. Their study was conducted on 791 patients, of those, 422 were depressed.…”

Section: Discussionmentioning

confidence: 99%

Evaluate the prevalence of depression in type 2 diabetics with microvascular complications

Khodabandehloo

Zarifkar

Eskandari

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

Introduction: Diabetes is one of the most common diseases in the world that is accompanied with many microvascular complications. Any chronic disease such as diabetes can cause types of mood disorders such as depression in patients. The aim of this study was to evaluate the prevalence of depression in type 2 diabetics with microvascular complications. Execution Method: In this cross-sectional study, type 2 diabetics with microvascular complications that referred to Hazrat Rasoul Akram Hospital during 2016–2017 were studied. After verification of retinopathy and nephropathy in patients, 100 patients were enrolled in the study and correlated between variables such as age, sex, body mass index, medication, education, retinopathy, nephropathy, marital status, hemoglobin A1c (HbA1c), triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL), blood pressure, and fasting blood sugar was investigated in patients given the possibility of depression. Results: The results of this study showed that 72% of patients were with depression and by evaluating the mentioned variables with depression disorder it was found that there was a significant relationship between fasting blood sugar, HbA1C, retinopathy, medication, and LDL with depression. Conclusion: Given the high prevalence of depression (72%) in diabetics in this study, it seems that psychiatric consultation is needed to diagnose depression in diabetics.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluate the prevalence of depression in type 2 diabetics with microvascular complications

Khodabandehloo

Zarifkar

Eskandari

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

show abstract

“…To make a compelling and fair case of aHSCT in T1D, the complications of aHSCT need to be juxtaposed with the short- and long-term complications of T1D. It is important to realize that acute and possibly life threatening events related to T1D and insulin treatment such as a hypoglycemic coma ( 32 ) and diabetic ketoacidosis (DKA) ( 33 ) are not uncommon. Indeed, T1D remains a deadly disease, where insulin therapy merely provides palliative care.…”

Section: Balancing the Risk Of Ahsct With The Risk Of Diabetes-associmentioning

confidence: 99%

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes

et al. 2018

View full text Add to dashboard Cite

“…Type 1 diabetes (T1D) affects 1.3 million patients in the US with 40,000 new patients annually. 1 An estimated 20 million are affected by T1D worldwide. 2 Lifespan is shortened 11-13 years 3 due to kidney and heart disease.…”

Section: Introductionmentioning

confidence: 99%

Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency

Gao

Giamouridis

Lai

et al. 2020

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

Type 1 diabetes affects 20 million patients worldwide. Insulin is the primary and commonly the sole therapy for type 1 diabetes. However, only a minority of patients attain the targeted glucose control and reduced adverse events. We tested urocortin 2 gene transfer as single-agent therapy for insulin deficiency using two mouse models. Urocortin 2 gene transfer reduced blood glucose for months after a single intravenous injection, through increased skeletal muscle insulin sensitivity, increased insulin release in response to glucose stimulation, and increased plasma insulin levels before and during euglycemic clamp. The combined increases in both insulin availability and sensitivity resulted in improved glycemic indices-events that were not anticipated in these insulin-deficient models. In addition, urocortin 2 gene transfer reduced ocular manifestations of long-standing insulin deficiency such as vascular leak and improved retinal function. Finally, mortality was reduced by urocortin 2 gene transfer. The mechanisms for these beneficial effects included increased activities of AMP-activated protein kinase and Akt (protein kinase B) in skeletal muscle, increased skeletal muscle glucose uptake, and increased insulin release. These data suggest that urocortin 2 gene transfer may be a viable therapy for new onset type 1 diabetes and might reduce insulin needs in later stage disease.

show abstract

The burden of severe hypoglycemia in type 1 diabetes

Cited by 37 publications

References 22 publications

Evaluate the prevalence of depression in type 2 diabetics with microvascular complications

Evaluate the prevalence of depression in type 2 diabetics with microvascular complications

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes

Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency

Contact Info

Product

Resources

About